Merck (MRK) shares closed up 1.07% at $149.88, outpacing the S&P 500's daily gain of 0.58% while the Dow Jones Industrial Average rose 0.69% and the Nasdaq Composite gained 1.05%. Despite this daily performance, the stock has declined 1.73% over the past month, underperforming both the Medical sector, which gained 3.5%, and the S&P 500, which rose 0.97% during the same period.
Investors are focused on Merck's upcoming earnings release, scheduled for October 29, 2026. Consensus estimates project the company will report earnings per share of $2.12, a decrease of 17.83% from the prior-year quarter. Revenue is expected to reach $17.23 billion, representing a 0.25% drop compared to the year-ago quarter. For the full fiscal year, Zacks Consensus Estimates forecast earnings of $2.66 per share and revenue of $67.1 billion, indicating changes of -70.38% and +3.21%, respectively, from the previous year.
Recent analyst estimate revisions have been negative for Merck. Over the past month, the Zacks Consensus EPS estimate has moved 3.83% lower. Zacks notes that such modifications often reflect changing near-term business trends, with positive revisions typically signaling analyst optimism about profitability. The firm's research suggests a direct relationship between these estimate changes and upcoming stock price performance.
Based on these metrics, Merck currently holds a Zacks Rank of #5 (Strong Sell). The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell) and has an outside-audited track record of outperformance since 1988, with #1 stocks returning an average of +25% annually.
Valuation metrics indicate Merck trades at a premium relative to its peers. The company's Forward P/E ratio stands at 55.8, significantly higher than the industry average Forward P/E of 17.25 for Large Cap Pharmaceuticals. Additionally, Merck's PEG ratio is 6.85, compared to an average of 2.04 for the Large Cap Pharmaceuticals industry as of the market close yesterday.
The broader industry context remains weak. The Large Cap Pharmaceuticals group, part of the Medical sector, holds a Zacks Industry Rank of 219, placing it in the bottom 11% of all more than 250 industries tracked by Zacks. This ranking gauges strength by measuring the average Zacks Rank of individual stocks within the group. Zacks research indicates that top 50% rated industries outperform the bottom half by a factor of 2 to 1.